Michael Davies

Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease

Philip Smith, K. Bodger, S. Dodd, 2020, Alimentary pharmacology & therapeutics.

From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn’s disease

S. Dodd, P. Collins, A. Konidari, 2020, Scandinavian journal of gastroenterology.

Safety and effectiveness of ustekinumab in elderly Crohn’s disease patients

J. Limdi, S. Subramanian, P. Flanagan, 2022, European journal of gastroenterology & hepatology.